Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the bottom line, with a GAAP Net Loss of $16.6M vs. $22.4M expected, and GAAP EPS of -$0.20 vs. -$0.30 expected. While the company is in a pre-revenue clinical stage, total operating expenses were managed well at $18.1M. A successful $87.5M financing in May boosted cash reserves to $190.0M, extending the operational runway into 2H 2028 and supporting the upcoming Phase 1 initiation for HWK-206 in Q3 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Whitehawk Therapeutics(WHWK) the EBIT is -18.11 M (+66.92%), Beat estimate;the EPS is -0.2 (+73.68%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
-0.00B--
----
EBITExceed expectations
-0.02B66.92%
-0.02B55.77%
+0.01B11.15%
EPSExceed expectations
-0.273.68%
-0.301360.36%
+0.101313.32%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf